Fesoterodine

Modify Date: 2024-01-11 12:30:12

Fesoterodine structure	Common Name	Fesoterodine
	CAS Number	286930-02-7	Molecular Weight	412.58500
	Density	1.043	Boiling Point	518.9ºC at 760 mmHg
	Molecular Formula	C₂₆H₃₇NO₃	Melting Point	N/A
	MSDS	N/A	Flash Point	267.6ºC

Use of Fesoterodine

Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB)[1][2].

Name	[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
Synonym	More Synonyms

Description	Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB)[1][2].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	pKi: 8.0 (M1), 7.7 (M2), 7.4 (M3), 7.3 (M4) and 7.5 (M5)[3]
In Vitro	Fesoterodine decreases micturition frequency, urgency severity and urgency incontinence episodes and increases the volume voided with each micturition[1]. After oral administration, Fesoterodine is rapidly and extensively hydrolysed in plasma by nonspecific esterases to Desfesoterodine (5-hydroxymethyl tolterodine; SPM 7605; HY-76569; an active metabolite of Fesoterodine)[3][4].
In Vivo	Fesoterodine (0.01-1 mg/kg; IV) reduces the micturition pressure and increases bladder capacity and ICIs (intercontraction intervas) at the lowest dose tested of 0.01 mg/kg[3]. Animal Model: Bladders from female Sprague-Dawley rats (225-275 g)[3] Dosage: 0.01, 0.1 and 1 mg/kg Administration: IV Result: Reduced the micturition pressure and increased bladder capacity and ICIs at the lowest dose tested of 0.01 mg/kg.
References	[1]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18. [2]. Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats [3]. Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42. [4]. Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96.

Density	1.043
Boiling Point	518.9ºC at 760 mmHg
Molecular Formula	C₂₆H₃₇NO₃
Molecular Weight	412.58500
Flash Point	267.6ºC
Exact Mass	412.28500
PSA	49.77000
LogP	5.48800

Precursor 9
CAS#:1390644-37-7 (R)-2-(3-(diiso... CAS#:1390644-50-4 (R)-2-(3-(diiso... CAS#:1390644-52-6 2-((R)-3-(diiso... CAS#:97-72-3 Isobutyric acid...
CAS#:207679-81-0 5-hydroxymethyl... CAS#:79-30-1 2-Methylpropano... CAS#:1206695-46-6 Fesoterodine L-... CAS#:156755-35-0 3-[(1R)-3-[Bis(...
CAS#:156755-23-6 6-Bromo-4-pheny...
DownStream 0